Acies Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-08-2024
- Paid Up Capital ₹ 0.10 M
as on 17-08-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 Cr
as on 17-08-2024
- Revenue 30.63%
(FY 2023)
- Profit 106.90%
(FY 2023)
- Ebitda 42.51%
(FY 2023)
- Net Worth 90.89%
(FY 2023)
- Total Assets 36.29%
(FY 2023)
About Acies Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 Cr.
Bhasker Dabral and Sujata Dabral serve as directors at the Company.
- CIN/LLPIN
U74999UR2019PTC009735
- Company No.
009735
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Apr 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Acies Pharmaceutical?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhasker Dabral  | Director | 19-Apr-2019 | Current |
| Sujata Dabral | Director | 19-Apr-2019 | Current |
Financial Performance of Acies Pharmaceutical.
Acies Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 30.63% increase. The company also saw a substantial improvement in profitability, with a 106.9% increase in profit. The company's net worth Soared by an impressive increase of 90.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acies Pharmaceutical?
Unlock access to Acies Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Alexon Healthcare Private LimitedActive 2 years 2 monthsBhasker Dabral and Sujata Dabral are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 24 Jan 2024 | ₹3.60 Cr | Open |
Others Creation Date: 29 Jan 2022 | ₹1.40 Cr | Open |
How Many Employees Work at Acies Pharmaceutical?
Unlock and access historical data on people associated with Acies Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acies Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acies Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
